Back to Journals » HIV/AIDS - Research and Palliative Care » Volume 5

Serum selenium and skin diseases among Nigerians with human immunodeficiency virus/acquired immune deficiency syndrome

Authors Akinboro AO, Mejiuni DA, Onayemi O, Ayodele OE, Atiba AS, Bamimore GM

Received 7 April 2013

Accepted for publication 15 May 2013

Published 20 August 2013 Volume 2013:5 Pages 215—221

DOI https://doi.org/10.2147/HIV.S46364

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Adeolu Oladayo Akinboro,1 David Ayodele Mejiuni,2 Olaniyi Onayemi,3 Olugbenga Edward Ayodele,4 Adeniran Samuel Atiba,5 Gbenga Micheal Bamimore6

1Dermatology Unit, Department of Internal Medicine, College of Health Sciences, Osogbo, and LAUTECH Teaching Hospital, Ogbomoso, Oyo State, Nigeria; 2Bullsbrook Medical Practice, Perth, WA, Australia; 3Department of Dermatology and Venereology, College of Health Science, Obafemi Awolowo University and OAUTHC, Ile – Ife, Osun State, Nigeria; 4Department of Internal Medicine, College of Health Sciences, Osogbo and LAUTECH Teaching Hospital, Ogbomoso, Oyo State, Nigeria; 5Department of Chemical Pathology, College of Medicine, Ekiti State University, and Ekiti State University Teaching Hospital, Ekiti State, Nigeria; 6Dermatology Unit, Department of Internal Medicine, LAUTECH Teaching Hospital, Ogbomoso, Oyo State, Nigeria

Background: The role of selenium as an antioxidant micronutrient has garnered the unprecedented focus of researchers in recent times. No clinical study has related serum selenium concentration to skin diseases in human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients.
Methods: In this study, 134 newly diagnosed HIV patients that satisfied the inclusion criteria were included. Skin diseases were clinically diagnosed and fasting venous blood was taken for assessment of serum selenium using an atomic absorption spectrophotometer.
Results: The mean age of HIV subjects with and without skin disease were not significantly different: 32.72 ± 9.21 versus 35.86 ± 8.55 years, P = 0.077, respectively. The mean of serum selenium (0.51 ± 0.48 versus 0.81 ± 0.39), CD4+ count (228.06 ± 212.89 versus 446.41 ± 182.87), and body mass index (BMI; 21.09 ± 3.58 versus 23.53 ± 3.35) were significantly lower (P < 0.001) for HIV/AIDS participants with skin disease than those without skin disease. We found significant clustering of symptoms and signs: fever (P = 0.037), weight loss (P = 0.009), oral candidiasis (P = 0.038), pallor (P = 0.037) among HIV/AIDS subjects with skin diseases than those without. Low serum selenium concentration was significantly associated with primary skin disease of HIV/AIDS, such as pruritic papular eruption of AIDS (P = 0.003), xeroderma (P = 0.030), fluffy hair (P = 0.021), blue-black nail hyperpigmentation (P = 0.033) and secondary skin disease, such as oral candidiasis (P = 0.002). There was a significant association between low serum selenium concentration and increasing frequency of skin diseases (P = 0.002), but serum selenium was not significantly related to extents of distribution of skin diseases (P > 0.05).
Conclusion: serum selenium concentration was lower among HIV subjects with skin diseases than those without skin disease. Pruritic papular eruption, xeroderma, fluffy hair, blue-black nail hyper pigmentation, and oral candidiasis were significantly associated with low serum selenium concentration.

Keywords: serum selenium, HIV/AIDS, skin disease, Osogbo, Nigeria

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]